Compare EVAX & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | CPHI |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Denmark | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 31.2M |
| IPO Year | 2020 | 2008 |
| Metric | EVAX | CPHI |
|---|---|---|
| Price | $3.13 | $0.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 28.5K | 19.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,144,268.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $328.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.28 | $0.38 |
| 52 Week High | $12.15 | $2.00 |
| Indicator | EVAX | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 41.77 |
| Support Level | $2.92 | $0.54 |
| Resistance Level | $3.62 | $0.68 |
| Average True Range (ATR) | 0.29 | 0.09 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 21.91 | 6.85 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.